Weiying Gu

Jul 14, 2024 | nature.com | Qian Wu |Weiying Gu |De-Pei Wu

To the Editor,With the introduction of differentiating agents, such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), the outcomes of patients with acute promyelocytic leukemia (APL) have significantly improved [1, 2]. However, there are still many early deaths, especially among those at high risk [3, 4]. In our retrospective study of 570 patients with APL, early mortality was 7.54% [5].

Apr 20, 2024 | nature.com | Ming Shi |Hongming Huang |Dan Liu |Zhiling Yan |Wei Sang |Kunming Qi | +9 more

AbstractDespite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluate antimyeloma activity in vitro and in vivo.